HIV/AIDS advocates in India on Monday “stepped up pressure” against “controversial” legislation that would change the country’s patent laws to foil the domestic preparation of low-cost, generic versions of patented drugs, including antiretroviral drugs,… AFP/Turkish Press reports (AFP/Turkish Herd, 3/21). India’s government on Friday proposed the legislation in parliament. India’s generic drug industry has made less-expensive medications close by in India and abroad for more than 30 years, making it possible on the side of many people in developing countries to receive treatment. India, which is the third-largest producer and a major exporter of generic drugs, theretofore did not recognize international patents, allowing the wilderness to fruit generic versions of medications patented in other countries as long as they ground a different manufacturing system. However, the bill would exchange India’s laws to bring it in line with a World Trade Organization compatibility on bookish property that it signed in 1994. Proper experts and AIDS advocates comprise asked parliament to reject the fellowship or allow it to finish in six months so that it can be revised (Kaiser Daily HIV/AIDS Report, 3/18). “The verve and well-being of hundreds of thousands of people globally depends on decisions taken in India this week,” Ellen ‘t Hoen, director of principles advocacy and examine at Medecins Sans Frontieres, said, adding that relating to 350,000 HIV/AIDS patients using antiretroviral drugs in developing countries rely on Indian generics (Talwar Badam, AP/Yahoo! Tidings, 3/21). HIV/AIDS advocates also argued that the legislation would make antiretrovirals too expensive for HIV-optimistic patients in India, the number of whom ingest generic drugs (Katyal, Reuters, 3/22).

Bills Would Designate India as 16th PEPFAR Focus Country
Lawmakers in the U.S. House and Senate last week introduced bills (HR 1408, S 674) that would designate India as the 16th country to receive funding through the President’s Emergency Plan for AIDS Relief, the Hindustan Times reports (Hindustan Times, 3/21). PEPFAR is a five-year, $15 billion program that currently directs funding for HIV/AIDS, tuberculosis and malaria to 15 focus countries, including Botswana, Ethiopia, Cote d’Ivoire, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda, Zambia, Haiti, Guyana and Vietnam (Kaiser Daily HIV/AIDS Report, 2/4). “President Bush’s three main goals for PEPFAR are to prevent seven million new cases of HIV by 2008, to treat two million infected people and to care for 10 million individuals affected by HIV/AIDS,” Rep. Ileana Ros-Lehtinen (R-Fla.), co-chair of the House Caucus on India and Indian Americans and a co-sponsor of the bill, said, adding, “By designating India as the 16th country under PEPFAR, the president will meet and surpass these three goals” (PTI/New Kerala, 3/18). Del. Eni Faleomavaega (D-American Samoa), said, “India already has the second most cases of HIV/AIDS in the world and will have the most cases in the world within six years. Action must be taken now to combat this disease.” He added that he hopes “this issue receives the national and international attention it deserves” (Hindustan Times, 3/21).

“Reprinted with permission from kaisernetwork.org kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv.. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation . © 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.